Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective

Clinical Therapeutics

Volumn 39, Issue 5, 2017, Pages 1012-1025

  Thompson, Peter L ^a,b,c   Davis, Timothy M E ^b,d  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d FREMANTLE HOSPITAL   (Australia)

Author keywords

cardiovascular outcomes; GLP agonists; glucose lowering drugs; SGLT 2 inhibitors; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALBIGLUTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; MIGLITOL; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; VOGLIBOSE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG SAFETY; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; AGONISTS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; METABOLISM;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 85006753325     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.10.008     Document Type: Review

References (79)

1. 1 Grundy, S.M., Benjamin, I.J., Burke, G.L., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (1999), 1134–1146.
2. 2 Waugh, N., Cummins, E., Royle, P., et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 14 (2010), 1–248.
3. 3 American Diabetes Association (ADA). 5. Glycemic Targets. Diabetes Care 39 (2016), S39–S46.
4. 4 Ryden, L., Grant, P.J., Anker, S.D., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
5. 5 Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 837–853.
6. 6 Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
7. 7 Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
8. 8 Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
9. 9 Turnbull, F.M., Abraira, C., Anderson, R.J., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52 (2009), 2288–2298.
10. 10 Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
11. 11 Hayward, R.A., Reaven, P.D., Wiitala, W.L., et al. VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372 (2015), 2197–2206.
12. 12 Nathan, D.M., Cleary, P.A., Backlund, J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:25 (2005), 2643–2653.
13. 13 Davis, T.M., Chubb, S.A., Bruce, D.G., Davis, W.A., Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetes Obes Metab 18 (2016), 598–606.
14. 14 Guidance for Industry. Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). December 2008.
15. 15 DeFronzo, R.A., Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131 (1999), 281–303.
16. 16 The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 19:suppl 2 (1970), 747–830.
17. 17 Seltzer, H.S., A summary of criticisms of the findings and conclusions of the University Group Diabetes Program. Diabetes 21 (1972), 976–979.
18. 18 Gangji, A.S., Cukierman, T., Gerstein, H.C., et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30 (2007), 389–394.
19. 19 Riddle, M.C., Editorial: sulfonylureas differ in effects on ischemic preconditioning–is it time to retire glyburide?. J Clin Endocrinol Metab 88 (2003), 528–530.
20. 20 Varvaki Rados, D., Catani Pinto, L., Reck Remonti, L., et al. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PloS Med, 13, 2016, e1001992.
21. 21 Bailey, C.J., Turner, R.C., Metformin. N Engl J Med 334 (1996), 574–579.
22. 22 Cusi, K., DeFronzo, R.A., Metformin: a review of its metabolic effects. Diabetes Rev 6 (1998), 89–131.
23. 23 McCreight, L.J., Bailey, C.J., Pearson, E.R., Metformin and the gastrointestinal tract. Diabetologia 59 (2016), 426–435.
24. 24 UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
25. 25 Kirpichnikov, D., McFarlane, S.I., Sowers, J.R., Metformin: an update. Ann Intern Med 137 (2002), 25–33.
26. 26 Lamanna, C., Monami, M., Marchionni, N., Mannucci, E., Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13 (2011), 221–228.
27. 27 Boussageon, R., Supper, I., Bejan-Angoulvant, T., et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PloS Med, 9, 2012, e1001204.
28. 28 Scheen, A.J., Paquot, N., Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 39 (2013), 179–190.
29. 29 Maruthur, N.M., Tseng, E., Hutfless, S., et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 164 (2016), 740–751.
30. 30 American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care 34:Suppl 1 (2011), S11–S61.
31. 31 Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
32. 32 Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
33. 33 Diamond, G.A., Kaul, S., Rosiglitazone and cardiovascular risk. N Engl J Med 357 (2007), 938–939.
34. 34 Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
35. 35 Erdmann, E., Harding, S., Lam, H., Perez, A., Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab 18 (2016), 266–273.
36. 36 Lincoff, A.M., Wolski, K., Nicholls, S.J., Nissen, S.E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007), 1180–1188.
37. 37 Kernan, W.N., Viscoli, C.M., Furie, K.L., et al. IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
38. 38 Hernandez, A.V., Usmani, A., Rajamanickam, A., Moheet, A., Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11 (2011), 115–128.
39. 39 Azoulay, L., Yin, H., Filion, K.B., et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ, 344, 2012, e3645.
40. 40 Lewis, J.D., Habel, L.A., Quesenberry, C.P., et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314 (2015), 265–277.
41. 41 Chiasson, J.L., Josse, R.G., Gomis, R., et al. Acarbose for the prevention of diabetes mellitus: the STOP-NIDDM randomised trial. STOP-NIDDM Trial Research Group. Lancet 359 (2002), 2072–2077.
42. 42 Holman, R.R., Bethel, M.A., Chan, J.C., et al., ACE Study Group. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am Heart J 168 (2014), 23–29.
43. 43 Palmer, S.C., Mavridis, D., Nicolucci, A., et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316 (2016), 313–324.
44. 44 ORIGIN Trial Investigators, Gerstein, H.C., Bosch, J., Dagenais, G.R., Díaz, R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
45. 45 ClinicalTrials.gov. A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE). https://clinicaltrials.gov/ct2/show/NCT01959529?term=DEVOTE&rank=1. Accessed September 12, 2016.
46. 46 Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
47. 47 Nauck, M., Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18 (2016), 203–216.
48. 48 Scheen, A.J., Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 14 (2015), 505–524.
49. 49 White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
50. 50 Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
51. 51 Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
52. 52 Zannad, F., Cannon, C.P., Cushman, W.C., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
53. 53 McGuire, D.K., Van de Werf, F., Armstrong, P.W., et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: Secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 126–135.
54. 54 FDA. Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm. Accessed September 2, 2016.
55. 55 ClinicalTrials.gov. CAROLINA: Cardiovascular outcome study of linagliptin vs glimepiride in patients with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01243424?term=CAROLINA+Linagliptin&rank=1. Accessed September 2, 2016.
56. 56 ClinicalTrials.gov. CARMELINA: Cardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus. https://clinicaltrials.gov/ct2/show/NCT01897532? Accessed September 2, 2016.
57. 57 Ryan, D., Acosta, A., GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring) 23 (2015), 1119–1129.
58. 58 Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
59. 59 Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
60. 60 Margulies, K.B., Hernandez, A.F., Redfield, M.M., NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316 (2016), 500–508.
61. 61 ClinicalTrials.gov. SUSTAIN 6: Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes. https://clinicaltrials.gov/ct2/show/NCT01720446?term=SUSTAIN+6+Semaglutide&rank=1. Accessed September 2, 2016.
62. 62 Marso SP, Bain SC, Consoli A, et al, for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes [published online September 16, 2016]. N Engl J Med.
63. 63 ClinicalTrials.gov. EXSCEL: A Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus. https://clinicaltrials.gov/ct2/show/NCT01144338?term=EXSCEL+Exenatide&rank=1. Accessed September 2, 2016.
64. 64 ClinicalTrials.gov. REWIND: Researching cardiovascular events with a weekly incretin in diabetes. https://clinicaltrials.gov/ct2/show/NCT01394952?term=REWIND+Dulaglutide&rank=1. Accessed September 2, 2016.
65. 65 ClinicalTrials.gov. HARMONY: Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus. https://clinicaltrials.gov.ct2/show/NCT02465515?term=HARMONY+7&rank=6. Accessed October 15, 2016.
66. 66 Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications [published online July 28, 2016]. Circulation.
67. 67 Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
68. 68 Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., et al., EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 (2015), 2117–2128.
69. 69 Ryder, R.E.J., Defronzo, R.A., Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: the optimal combination may be metformin, pioglitazone and empagliflozin. Br J Diabetes Vasc Dis 15 (2015), 151–154.
70. 70 Ingelfinger, J.R., Rosen, C.J., Cardiovascular risk and sodium–glucose cotransporter 2 inhibition in type 2 diabetes. N Engl J Med 373 (2015), 2178–2179.
71. 71 Neal, B., Perkovic, V., de Zeeuw, D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J 166 (2013), 217–223 e211.
72. 72 CANVAS – CANagliflozin cardioVascular Assessment Study (CANVAS). ClinicalTrials.gov Identifier: NCT01032629. https://clinicaltrials.gov/ct2/show/NCT01032629. Accessed September 2, 2016.
73. 73 ClinicalTrials.gov. CREDENCE: Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy. https://clinicaltrials.gov/ct2/show/NCT02065791?term=CREDENCE+Canagliflozin&rank=1. Accessed September 2, 2016.
74. 74 Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). ClinicalTrials.gov Identifier: NCT01730534. https://clinicaltrials.gov/ct2/show/NCT01730534. Accessed September 2, 2016.
75. 75 ClinicalTrials.gov. VERTIS CV: Cardiovascular outcomes following ertugliflozin treatment in type 2 diabetes mellitus participants With vascular disease. https://clinicaltrials.gov/ct2/show/NCT01986881?term=Ertugliflozin&rank=12. Accessed September 2, 2016.
76. 76 Ettehad, D., Emdin, C.A., Kiran, A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
77. 77 Fitchett, D., Zinman, B., Wanner, C., et al. EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37 (2016), 1526–1534.
78. 78 Satttar, N., McLaren, J., Kristensen, S.L., et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.
79. 79 Scheen, A.J., Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Meta 42 (2016), 224–233.